Protamine requirements in cardiac surgery: Effect of changes in the heparin reference standard

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 28, Issue 5, 2014, Pages 1227-1232

  Taneja, Ravi ^a   Berry, Leslie ^b   Pappu, Unnikrishnan ^a   Stitt, Larry ^c   Sayal, Puneet ^d   Allen, Peter ^e   Hoogendoorn, Hugh ^f   Chan, Anthony ^b  

^a WESTERN UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

^f Hemostasis Reference Laboratory   (Canada)

Author keywords

anti IIa; cardiopulmonary bypass; heparin; protamine anti Xa

Indexed keywords

BLOOD CLOTTING FACTOR 10A; HEPARIN; PROTAMINE; PROTHROMBIN A;

AGED; ARTICLE; BOLUS INJECTION; CARDIAC PATIENT; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; HEART SURGERY; HOSPITAL ADMISSION; HUMAN; IN VITRO STUDY; LIMIT OF DETECTION; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; REFERENCE VALUE; SURGICAL PATIENT; TITRIMETRY; ANIMAL; BLOOD; FEMALE; MALE; MEDICINAL CHEMISTRY; MIDDLE AGED; PIG; PILOT STUDY; STANDARD; STANDARDS; TRENDS;

AGED; ANIMALS; CARDIAC SURGICAL PROCEDURES; CHEMISTRY, PHARMACEUTICAL; COHORT STUDIES; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; PROTAMINES; REFERENCE STANDARDS; SWINE;

EID: 84908218251     PISSN: 10530770     EISSN: 15328422     Source Type: Journal    
DOI: 10.1053/j.jvca.2014.04.024     Document Type: Article

References (33)

1. C.G. Koch, L. Li, and D.I. Sessler Duration of red-cell storage and complications after cardiac surgery N Engl J Med 358 2008 1229 1239
2. K. Karkouti, D.N. Wijeysundera, and T.M. Yau The independent association of massive blood loss with mortality in cardiac surgery Transfusion 44 2004 1453 1462
3. D. Paparella, S.J. Brister, and M.R. Buchanan Coagulation disorders of cardiopulmonary bypass: A review Intensive Care Med 30 2004 1873 1881
4. K.A. Arsenault, J.S. Paikin, and J. Hirsh Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial J Thorac Cardiovasc Surg 144 2012 944 950 e3
5. C.E. Gruenwald, C. Manlhiot, and A.A. Abadilla Heparin brand is associated with postsurgical outcomes in children undergoing cardiac surgery Ann Thorac Surg 93 2012 878 882
6. A. Galeone, C. Rotunno, and P. Guida Monitoring incomplete heparin reversal and heparin rebound after cardiac surgery J Cardiothorac Vasc Anesth 27 2013 853 858
7. J.H. Levy, and K.A. Tanaka Anticoagulation and reversal paradigms: Is too much of a good thing bad? Anesth Analg 108 2009 692 694
8. K.H. Teoh, E. Young, and M.H. Blackall Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery? J Thorac Cardiovasc Surg 128 2004 211 219
9. L. Shore-Lesserson, L.J. Enriquez, and J.A. Kaplan Coagulation monitoring: Kaplan's Cardiac Anesthesia. Elsevier Saunders St Louis 2011 496 517
10. T.F. Slaughter, and R.D. Miller Coagulation: Miller's anesthesia Churchill Livingstone Philadelphia, PA 2010 1767 1780
11. J. Hirsh, T.E. Warkentin, and S.G. Shaughnessy Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety Chest 119 2001 64S 94S
12. K. Kaushansky, and T. Kipps Drugs acting on the Blood and Blood forming organs: Goodman and Gilman's The Pharmacological Basis of Therapeutics 2006 McGraw Hill New York 1473 1488
13. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm207506.htm (Accessed 18 March 2014)
14. http://www.usp.org/sites/default/files/usp-pdf/EN/USPNF/pf35-5-IRA.pdf (Accessed 18 March 2014)
15. R. Taneja, P. Fernandes, and G. Marwaha Perioperative coagulation management and blood conservation in cardiac surgery: A Canadian Survey J Cardiothorac Vasc Anesth 22 2008 662 669
16. V.A. Ferraris, S.P. Ferraris, and S.P. Saha Perioperative blood transfusion and blood conservation in cardiac surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline Ann Thorac Surg 83 2007 S27 S86
17. M.A. Smythe, and J.M. Koerber Heparin monitoring: The confusion continues Pharmacotherapy 19 1999 1240 1242
18. M.A. Crowther, L.R. Berry, and P.T. Monagle Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin Br J Haematol 116 2002 178 186
19. R. Taneja, G. Marwaha, and P. Sinha Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery Can J Anaesth 56 2009 489 496
20. J. Butterworth, Y.A. Lin, and R.C. Prielipp Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass Ann Thorac Surg 74 2002 1589 1595
21. A. Racanelli, J. Fareed, and J.M. Walenga Biochemical and pharmacologic studies on the protamine interactions with heparin, its fractions and fragments Semin Thromb Hemost 11 1985 176 189
22. M. Wolzt, A. Weltermann, and M. Nieszpaur-Los Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man Thromb Haemost 73 1995 439 443
23. K.B. Komosińska-Vassev, K. Winsz-Szczotka, and K. Kuznik-Trocha Age-related changes of plasma glycosaminoglycans Clin Chem Lab Med 46 2008 219 224
24. X.J. Shi, J. Yang, and B. Shen Endogenous heparinoids induced massive hemorrhage postoperatively following THA Orthopedics 34 2011 207
25. M. Andrew, L. Mitchell, and L. Berry An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus J Clin Invest 89 1992 321 326
26. M.A. Delorme, N. Saeed, and A. Sevcik Plasma dermatan sulfate proteoglycan in a patient on chronic hemodialysis Blood 82 1993 3380 3385
27. D. Bolliger, F. Szlam, and M. Azran The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentrations Anesth Analg 111 2010 601 608
28. A.F. Ni, R.J. Preston, and P.V. Jenkins Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation Blood 114 2009 1658 1665
29. M. Mittermayr, C. Velik-Salchner, and B. Stalzer Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): Results of a pilot study Anesth Analg 108 2009 743 750
30. T. Mochizuki, P.J. Olson, and F. Szlam Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass Anesth Analg 87 1998 781 785
31. J.D. Olson, C.F. Arkin, and J.T. Brandt College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: Laboratory monitoring of unfractionated heparin therapy Arch Pathol Lab Med 122 1998 782 798
32. D.J. Murray, W.J. Brosnahan, and B. Pennell Heparin detection by the activated coagulation time: A comparison of the sensitivity of coagulation tests and heparin assays J Cardiothorac Vasc Anesth 11 1997 24 28
33. J.F. Hardy, S. Belisle, and D. Robitaille Measurement of heparin concentration in whole blood with the Hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X J Thorac Cardiovasc Surg 112 1996 154 161